首页> 外文期刊>Journal of Veterinary Internal Medicine >Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs
【24h】

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs

机译:埃索美拉唑对健康的比格犬静脉,口服和皮下给药后的药代动力学和抑酸功效

获取原文
       

摘要

BackgroundEsomeprazole is an S-enantiomer of omeprazole that has favorable pharmacokinetics and efficacious acid suppressant properties in humans. However, the pharmacokinetics and effects on intragastric pH of esomeprazole in dogs have not been reported. ObjectiveTo determine the pharmacokinetics of esomeprazole administered via various routes (PK study) and to investigate the effect of esomeprazole on intragastric pH with a Bravo pH monitoring system (PD study). AnimalsSeven adult male Beagle dogs and 5 adult male Beagle dogs were used for PK and PD study, respectively. MethodsBoth studies used an open, randomized, and crossover design. In the PK study, 7 dogs received intravenous (IV), subcutaneous (SC), and oral doses (PO) of esomeprazole (1 mg/kg). Each treatment period was separated by a washout period of at least 10 days. Esomeprazole plasma concentrations were measured by HPLC/MS/MS. In the efficacy study, intragastric pH was recorded without medication (baseline pH) and following IV, SC, and PO esomeprazole dosing regimens (1 mg/kg) in 5 dogs. ResultsThe bioavailability of esomeprazole administered as PO enteric-coated granules and as SC injections was 71.4 and 106%, respectively. The half-life was approximately 1 hour. Mean ± SD percent time intragastric pH was ≥3 and ≥4 was 58.9 ± 21.1% and 40.9 ± 17.3% for IV group, 75.8 ± 16.4% and 62.7 ± 17.7% for SC group, 88.2 ± 8.9% and 82.5 ± 7.7% for PO group, and 12.5 ± 3.6% and 3.7 ± 1.8% for baseline. The mean percent time with intragastric pH was ≥3 or ≥4 was significantly increased regardless of the dosing route ( P ConclusionThe PK parameters for PO and SC esomeprazole administration were favorable, and esomeprazole significantly increased intragastric pH after IV, PO, and SC administration. IV and SC administration of esomeprazole might be useful when PO administration is not possible. No significant adverse effects were observed.
机译:背景埃索美拉唑是奥美拉唑的S对映异构体,在人体中具有良好的药代动力学和有效的酸抑制特性。但是,尚未报道埃索美拉唑对犬的药代动力学及其对胃内pH的影响。目的通过多种途径确定埃索美拉唑的药代动力学(PK研究),并通过Bravo pH监测系统研究埃索美拉唑对胃内pH的影响(PD研究)。动物分别使用七只成年雄性比格犬和5只成年雄性比格犬进行PK和PD研究。方法两项研究均采用开放,随机和交叉设计。在PK研究中,有7只狗接受了埃索美拉唑的静脉内(IV),皮下(SC)和口服剂量(PO)(1 mg / kg)。每个治疗期至少间隔10天。埃索美拉唑血浆浓度通过HPLC / MS / MS测定。在功效研究中,记录了5只狗在未用药的情况下(胃内pH)和静脉,SC和PO埃索美拉唑给药方案(1 mg / kg)后的胃内pH。结果埃索美拉唑作为PO肠溶颗粒剂和SC注射剂的生物利用度分别为71.4%和106%。半衰期约为1小时。静脉注射组的平均胃内pH值百分比时间≥3和≥4分别为IV组的58.9±21.1%和40.9±17.3%,SC组的75.8±16.4%和62.7±17.7%,SC组的88.2±8.9%和82.5±7.7% PO组,基线为12.5±3.6%和3.7±1.8%。不论给药途径如何,胃内pH值≥3或≥4的平均百分比时间均显着增加(P结论静脉,口服和SC给药后,PO和SC埃索美拉唑的PK参数良好,埃索美拉唑显着增加了胃内pH。当不能口服给药时,埃索美拉唑的IV和SC给药可能是有用的,未观察到明显的不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号